# Vassili Valayannopoulos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vassili-valayannopoulos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,242 |
| Field | Metabolism and Genetic Disorders |
| h-index | 55 |
| i10-index | 123 |
| Last Known Institution | Regeneron (United States) |
| OpenAlex ID | https://openalex.org/A5050773134 |
| ORCID iD | 0000-0003-3942-8234 |
| Works | 257 |

## Researcher papers

- [Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia](https://scholariq.org/papers/proposed-guidelines-for-the-diagnosis-and-management-of-methylmalonic-and/)
- [Suggested guidelines for the diagnosis and management of urea cycle disorders](https://scholariq.org/papers/suggested-guidelines-for-the-diagnosis-and-management-of-urea-cycle-disorders/)
- [Congenital hyperinsulinism: current trends in diagnosis and therapy](https://scholariq.org/papers/congenital-hyperinsulinism-current-trends-in-diagnosis-and-therapy/)
- [Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study](https://scholariq.org/papers/long-term-outcome-of-hurler-syndrome-patients-after-hematopoietic-cell/)
- [Mucopolysaccharidosis VI](https://scholariq.org/papers/mucopolysaccharidosis-vi/)
- [The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation](https://scholariq.org/papers/the-phenotypic-spectrum-of-organic-acidurias-and-urea-cycle-disorders-part-1-the/)
- [A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency](https://scholariq.org/papers/a-phase-3-trial-of-sebelipase-alfa-in-lysosomal-acid-lipase-deficiency/)
- [The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype](https://scholariq.org/papers/the-phenotypic-spectrum-of-organic-acidurias-and-urea-cycle-disorders-part-2-the/)
- [Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure](https://scholariq.org/papers/enzyme-replacement-therapy-and-or-hematopoietic-stem-cell-transplantation-at/)
- [Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study](https://scholariq.org/papers/efficacy-and-safety-of-enzyme-replacement-therapy-with-bmn-110-elosulfase-alfa/)
- [Clinical Characteristics, Developmental Trajectory, and Caregiver Burden of Patients With Creatine Transporter Deficiency ( <i>SLC6A8</i> )](https://scholariq.org/papers/clinical-characteristics-developmental-trajectory-and-caregiver-burden-of/)

## Researcher topics

- [Metabolism and Genetic Disorders](https://scholariq.org/topics/metabolism-and-genetic-disorders/)
- [Lysosomal Storage Disorders Research](https://scholariq.org/topics/lysosomal-storage-disorders-research/)
- [Biomedical Research and Pathophysiology](https://scholariq.org/topics/biomedical-research-and-pathophysiology/)
- [Glycogen Storage Diseases and Myoclonus](https://scholariq.org/topics/glycogen-storage-diseases-and-myoclonus/)
- [Mitochondrial Function and Pathology](https://scholariq.org/topics/mitochondrial-function-and-pathology/)

## Researcher university

- [Regeneron (United States)](https://scholariq.org/institutions/regeneron-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.